Maryland | 1-32261 (BioMed Realty Trust,Inc.) 000-54089 (BioMed Realty, L.P.) |
20-1142292 (BioMed Realty Trust, Inc.) 20-1320636 (BioMed Realty, L.P.) |
||
(State or Other Jurisdiction of Incorporation) |
(Commission File No.) | (I.R.S. Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| 100% of the principal amount of the Notes being redeemed; or |
| the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis at the adjusted treasury rate (determined in accordance with the Indenture) plus 0.30%, |
plus, in each case, accrued and unpaid interest thereon to the redemption date. |
| a default for 30 days in the payment of any installment of interest under the Notes; |
| a default in the payment of the principal amount or redemption price due with respect to the Notes, when the same becomes due and payable; |
| failure to pay any indebtedness for money borrowed by the Operating Partnership, the Company, or any subsidiary in which the Operating Partnership has invested at least $50 million in capital (a Significant Subsidiary), in an outstanding principal amount in excess of $50 million at final maturity or upon acceleration after the expiration of any applicable grace period, which indebtedness is not discharged, or such default in payment or acceleration is not cured or rescinded, within 30 days after written notice to the Operating Partnership from the Trustee (or to the Operating Partnership and the Trustee from holders of at least 25% in principal amount of the outstanding Notes); |
| default in the performance or breach of any other covenant or warranty by the Operating Partnership or the Company in the Indenture (other than a covenant or warranty that has been included in the Indenture solely for the benefit of a series of debt securities other than the Notes), which default continues uncured for a period of 60 days after the Operating Partnership receives written notice from the Trustee (or the Operating Partnership and the Trustee receive written notice from the holders of at least 25% in principal amount of the outstanding Notes) as provided in the Indenture; and |
| certain events of bankruptcy, insolvency or reorganization of the Operating Partnership, the Company or any Significant Subsidiary. |
Exhibit | ||
Number | Description of Exhibit | |
4.1
|
Indenture, dated March 30, 2011, by and among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee. |
Exhibit | ||
Number | Description of Exhibit | |
4.2
|
Supplemental Indenture No. 1, dated March 30, 2011, by and among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee, including the form of 3.85% Senior Notes due 2016 and guarantee thereof. | |
5.1
|
Opinion of Venable LLP. | |
5.2
|
Opinion of Latham & Watkins LLP. | |
23.1
|
Consent of Venable LLP (included in Exhibit 5.1). | |
23.2
|
Consent of Latham & Watkins LLP (included in Exhibit 5.2). |
Date: March 30, 2011 | BIOMED REALTY TRUST, INC. |
|||
By: | /s/ GREG N. LUBUSHKIN | |||
Name: | Greg N. Lubushkin | |||
Title: | Chief Financial Officer | |||
BIOMED REALTY, L.P. |
||||
By: | BioMed Realty Trust, Inc. | |||
its General Partner | ||||
By: | /s/ GREG N. LUBUSHKIN | |||
Name: | Greg N. Lubushkin | |||
Title: | Chief Financial Officer | |||